Clinical Trials · NCT00432068

Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers

Name: Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Octreotide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Novartis Pharmaceuticals
Enrollment: 48
Start date: Jan 2007
Locations: 6 sites, 3 countries
Primary endpoint: Pharmacokinetics of a single dose of an extended long-acting formulation of octreotide pamoate

View Octreotide compound reference